Print Identification of Microorganisms Using Nucleic Acid Probes

Identification of Microorganisms Using Nucleic Acid Probes



Until recently, identification of microorganisms depended either on culture of body fluids or tissues or identification of antigens, using a variety of techniques including direct fluorescent antibody technique and qualitative or quantitative immunoassays. These techniques are problematic when the microorganism exists in very small numbers or is technically difficult to culture. Indirect identification of microorganisms by immunoassays for specific antibodies reactive with the microorganism is limited by the inability to distinguish between past exposure and current infection; although to some extent immunoglobulin M (IgM) versus IgG antibodies can be helpful. Response to treatment is typically assessed according to the patient's clinical response or by rising titers of specific antibodies and falling antigen titers.

The availability of nucleic acid probes has permitted the rapid direct identification of microorganisms' DNA or RNA. Amplification techniques result in exponential increases in copy numbers of a targeted strand of microorganism-specific DNA. The most commonly used amplification technique is PCR or reverse transcriptase (RT)-PCR. In addition to PCR, other nucleic acid amplification techniques have been developed such as transcription-mediated amplification, loop-mediated isothermal DNA amplification (LAMP), strand displacement amplification, nucleic acid sequence-based amplification, and branched chain DNA signal amplification. After amplification, target DNA can be readily detected using a variety of techniques. The amplified product can also be quantified to give an assessment of how many microorganisms are present. Quantification of the amount of nucleic acids permits serial assessments of response to treatment;  the most common clinical application of quantification is the serial measurement of HIV RNA (called viral load), which serves as a prognostic factor.

Until 1998, these nucleic acid probe techniques were coded using nonspecific CPT codes describing the multiple steps in the laboratory process. However, in 1998, the CPT codes were revised to include a series of new codes that describe the direct probe technique, amplified probe technique, and quantification for 22 different microorganisms. These series of CPT codes were introduced as a group; however at present, probe technologies and clinical applications for some microorganisms are either not widely disseminated or are used primarily for research purposes. In addition, CPT codes have been added for additional microorganisms, such as Staphylococcus aureus. A number of different microorganisms are reviewed as follows:

Bartonella henselae or quintana: Bartonella henselae or quintana is thought to be responsible for cat scratch disease, which is characterized by chronic regional lymphadenopathy developing about 2 weeks after contact with a cat. A cat scratch skin antigen test is positive in the majority of patients with cat scratch disease, but this test cannot distinguish between active and remote infection.

Bartonella may also cause an opportunistic infection in HIV-infected patients, where it is characterized by an acute febrile bacteremic illness, evolving  to an asymptomatic bacteremia and finally indolent vascular skin lesions. The organism is typically detected using culture techniques, although an incubation period of 5 to more than 30 days is required. DNA probe technology has been investigated as a diagnostic technique.

Borrelia burgdorferi: Borrelia burgdorferi is responsible for Lyme disease. The clinical symptoms and diagnosis of Lyme disease are more thoroughly discussed in Intravenous Antibiotic Therapy for Lyme Disease policy. Antibody assays are typically the first diagnostic laboratory test performed; but these assays may be negative during early disease, and, in the later course of the disease, immunologic assays cannot distinguish between past and present infections, a severe limiting factor in areas of high prevalence. The spirochete is also difficult to culture, in part because the number of organisms in clinical specimens is extremely low. The highest sensitivities have been reported from synovial fluid samples; the sensitivity of the PCR technique for cerebrospinal fluid, blood, and urine have been disappointing (low and/or variable). Therefore, in some limited instances, PCR amplification has been used to confirm the diagnosis of active Lyme disease.

Candida species: A commonly occurring yeast, Candida species can be normally found on diseased skin, throughout the entire GI tract, expectorated sputum, the female genitalia, and in urine of patients with indwelling Foley catheters. Clinically significant candida infections are typically diagnosed by clinical observation or by identification of the yeast forms on biopsy specimens. Candida species are a common cause of bacterial vaginosis.

Chlamydia pneumoniae: Chlamydia pneumoniae is an important cause of pneumonia, bronchitis, and sinusitis. Culture and isolation of the microorganism is difficult; a microimmunofluorescence serum test may be used. The use of PCR amplification now offers a rapid diagnosis.

Chlamydia trachomatis: Chlamydia trachomatis is a significant intracellular pathogen causing, most prominently, urogenital disease (including pelvic inflammatory disease) and perinatal infections. Chlamydia trachomatis is also responsible for lymphogranuloma venereum (LGV). Due to its prevalence and association with pelvic inflammatory disease and perinatal disease, widespread testing of chlamydia is recommended; routine chlamydia testing has been adopted as a quality measure by HEDIS 3.0. This microoganism can be diagnosed by: 1) identifying the typical intracytoplasmic inclusions in cytology specimens; 2) isolation in tissue culture; 3) demonstration of chlamydial antigen by enzyme-linked immunosorbent assay or by immunofluorescent staining; or 4) demonstration of DNA using a direct probe or amplification technique.

Clostridium difficile: Clostridium difficile is an anaerobic, toxin-producing bacteria present in the intestinal tract. It causes clinical colitis when the normal intestinal flora is altered and overgrowth of C difficile occurs. The common precipitant that disrupts the normal intestinal flora is previous treatment with antibiotics. The disorder has varying severity but can be severe and in extreme cases, life-threatening. C difficile is easily spread from person-to-person contact and is a common cause of hospital-acquired outbreaks. Hospital infection control measures, such as wearing gloves and handwashing with soap and water, are effective methods of reducing the spread of C difficile. The standard diagnosis is made by an assay for the C difficile cytotoxin or by routine culture methods.

Cytomegalovirus: Cytomegalovirus (CMV) is a common virus that infects many, but rarely causes clinical disease in healthy individuals. However, this virus can cause protean disease syndromes, most prominently in immunosuppressed patients, including transplant recipients or those infected with the HIV virus. CMV can also remain latent in tissues after recovery of the host from an acute infection. Diagnosis depends on demonstration of the virus or viral components or demonstration of a serologic rise. DNA probe techniques, including amplification, have also been used to identify patients at risk for developing CMV disease as a technique to triage antiviral therapy.

Enterovirus: Enteroviruses are single-stranded RNA viruses. This group of viruses includes the polioviruses, coxsackieviruses, echoviruses, and other enteroviruses. In addition to 3 polioviruses, there are more than 60 types of nonpolio enteroviruses that can cause disease in humans. Most people who are infected with a nonpolio enterovirus have no disease symptoms at all. Infected persons who develop illness usually develop either mild upper respiratory symptoms, flu-like symptoms with fever and muscle aches, or an illness with rash. Less commonly, some persons have "aseptic" or viral meningitis. The use of amplified probe DNA test(s) can be used to detect enteroviruses.

Gardnerella vaginalis: A common microorganism, Gardnerella vaginalis is typically found in the human vagina and is usually asymptomatic. However, G. vaginalis is found in virtually all women with bacterial vaginosis, and is characterized by inflammation and perivaginal irritation. The microorganism is typically identified by culture. The role of G vaginalis in premature rupture of membranes and preterm labor is also under investigation.

Hepatitis B, C, and G: Hepatitis is typically diagnosed by a pattern of antigen and antibody positivity. However, the use of probe technology permits the direct identification of hepatitis DNA or RNA, which may also provide prognostic information. Quantification techniques are used as a technique for monitoring the response to interferon and/or ribavarin therapy in patients with hepatitis C.

Herpes simplex virus (HSV): Herpes simplex infection of the skin and mucous membranes is characterized by a thin-walled vesicle on an inflammatory base typically in the perioral, ocular, or genital areas, although any skin site may be involved. The diagnosis may depend on pathologic examination of cells scraped from a vesicle base or by tissue culture techniques. Herpes simplex encephalitis is one of the most common and serious sporadic encephalitides in immunocompetent adults. The PCR technique to detect HSV in the cerebrospinal fluid has been used to provide a rapid diagnosis of herpes virus encephalitis.

Herpes virus-6: Human herpes virus-6 (HHV-6) is widespread in the general population and is also responsible for roseola, a benign rash and fever occurring in young children. HHV-6 may also cause meningitis, encephalitis, pneumonitis and hepatitis in children and adults. Diagnosis is typically based on rising serologic titers.

HIV-1, HIV-2: DNA probe technology for HIV-1 is widely disseminated, and HIV-1 quantification has become a standard laboratory test in HIV-1 infected patients. HIV-2 can result in severe immunosuppression and the development of serious opportunistic diseases. Although HIV-2 has been reported in the United States, it is most commonly found in Western Africa. Blood donations are routinely tested for HIV-2, but due to its rarity in this country, clinical testing for HIV-2 is typically limited to those with contact with persons in a country where HIV-2 is endemic, or when the clinical picture suggests HIV infection, but testing for HIV-1 is negative.

Influenza virus: Influenza virus is a very common pathogen that accounts for a high burden of morbidity and mortality, especially in elderly and immunocompromised patients. The most common means of identifying influenza is by viral culture, which takes 48-72 hours to complete. Influenza is highly contagious and has been the etiology of numerous epidemics and pandemics. Identification of outbreaks is important so that isolation measures may be undertaken to control the spread of disease. Anti-viral treatment can be effective if instituted early in the course of disease. Therefore, rapid identification of influenza virus is important in making treatment decisions for high-risk patients and in instituting infection control practices.

Legionella pneumophila: Legionella pneumophila is among the most common microbial etiologies of community acquired pneumonia. Laboratory diagnosis depends on culture, direct fluorescent antibody tests, urinary antigens, or DNA probe. DNA probe techniques have also been used in epidemiologic investigations to identify the source of a legionella outbreak.

Mycobacteria species: Although mycobacterium can be directly identified in sputum (i.e. acid fast bacilli), these organisms may take 9 to 16 days to culture. DNA probes have also been used to identify specific mycobacterial groups (i.e., mycobacterial tuberculosis, avian complex, or intracellular) after culture. In addition, amplification techniques for mycobacterium tuberculosis may be used in patients who have a positive smear. The rapid identification of M. tuberculosis permits prompt isolation of the patient and identification of the patient's contacts for further testing.

Mycoplasma pneumoniae: Mycoplasma pneumoniae is an atypical bacterium that is a common cause of pneumonia. It is most prevalent in younger patients, younger than age 40 years and in individuals who live or work in crowded areas such as schools or medical facilities. The infection is generally responsive to antibiotics of the macrolide or quinolone class. Most patients with M pneumonia recover completely, although the course is sometimes prolonged for up to 4 weeks or more. Extrapulmonary complications of M pneumonia occur uncommonly, including hemolytic anemia and the rash of erythema multiforme.

Neisseria gonorrhoeae: Isolation by culture is the conventional form of diagnosis for this common pathogen. Direct DNA probes and amplification techniques have also been used. Neisseria is often tested for at the same time as chlamydia.

Papillomavirus: Papillomavirus species are common pathogens that produce epithelial tumors of the skin and mucous membranes, most prominently the genital tract. Physical examination is the first diagnostic technique. Direct probe and amplification procedures have been actively investigated in the setting of cervical lesions. The ViraPap test is an example of a commercially available direct probe technique for identifying papillomavirus. There has also been interest in evaluating the use of viral load tests of papillomavirus to identify patients at highest risk of progressing to invasive cervical carcinoma.

Streptococcus, group A: Also referred to as S treptococcus pyogenes, this pathogen is the most frequent cause of acute bacterial pharyngitis. It can also give rise to a variety of cutaneous and systemic conditions, including rheumatic fever and post-streptococcal glomerulonephritis. Throat culture is the preferred method for diagnosing S. pharyngitis. In addition, a variety of commercial kits are now available that use antibodies for the rapid detection of group A carbohydrate antigen directly from throat swabs. While very specific, these kits are less sensitive than throat cultures, so a negative test may require confirmation from a subsequent throat culture. DNA probes have also been used for direct identification of streptococcus, and can be used as an alternative to a throat culture as a back-up test to a rapid, office-based strep test.

Streptococcus, group B (GBS): Also referred to as Streptococcus agalactiae, GBS is the most common cause of sepsis, meningitis, or death among newborns. Early onset disease, within 7 days of birth, is related to exposure to GBS colonizing the mother's anogenital tract during birth. The Centers for Disease Control and Prevention (CDC), the American College of Obstetrics and Gynecology (ACOG), and the American Academy of Pediatricians (AAP) recommend either maternal risk assessment or screening for GBS in the perinatal period. Screening consists of obtaining vaginal and anal specimens for culture at 35 to 37 weeks' gestation. The conventional culture and identification process requires 48 hours. Therefore there has been great interest in developing rapid assays using DNA probes to shorten the screening process, so that screening could be performed in the intrapartum period with institution of antibiotics during labor.

Trichomonas Vaginalis: Trichomonas is a single-cell protozoan that is a common cause of vaginitis. The organism is sexually transmitted and can infect the urethra or vagina. The most common way of diagnosing trichomonas is by clinical signs and by directly visualizing the organism by microscopy in a wet prep vaginal smear. Culture of trichimonas is limited by poor sensitivity. Treatment with metronidazole results in a high rate of eradication. The disease is usually self-limited without sequelae, although infection has been associated with premature birth and higher rates of HIV transmission, cervical cancer, and prostate cancer.



The status of nucleic acid identification using direct probe, amplified probe, or quantification for the microorganisms listed in the CPT book are summarized in the following table:



      Direct Probe        

Amplified Probe


Bartonella henselae or quintana




Borrelia burgdorferi




Candida species

Medically Necessary

Medically Necessary


Chlamydia pneumoniae




Chlamydia trachomatis

Medically Necessary

Medically Necessary


Clostridium difficile

Medically Necessary



Medically Necessary

Medically Necessary

Medically Necessary




Gardnerella vaginalis

Medically Necessary



Gastrointestinal Pathogen Panel 



Hepatitis B

Medically Necessary

Medically Necessary

Medically Necessary

Hepatitis C

Medically Necessary

Medically Necessary

Medically Necessary

Hepatitis G




Herpes simplex virus

Medically Necessary

Medically Necessary


Herpes virus-6





Medically Necessary

Medically Necessary

Medically Necessary


Medically Necessary

Medically Necessary

Medically Necessary

Influenza virus

Medically Necessary

Medically Necessary

Medically Necessary

Legionella pneumophila




Mycobacterium species

Medically Necessary



Mycobacterium tuberculosis

Medically Necessary

Medically Necessary


Mycobacterium avium intracellulare

Medically Necessary



Mycoplasma pneumoniae




Neisseria gonorrhoeae

Medically Necessary

Medically Necessary



Medically Necessary

Medically Necessary


Respiratory virus panel 

Medically Necessary

Staphylococcus aureus 

Medically Necessary

Staphylococcus aureus, methicillin resistant (MRSA) 

Medically Necessary

Streptococcus group A

Medically Necessary



Streptococcus group B


Medically Necessary


Trichomonas vaginalis

Medically Necessary

Medically Necessary

Vancomycin resistance (eg, enterococcus vanA, VanB) 


Medically Necessary







It should be noted that the technique for quantification includes both amplification and direct probes; therefore, simultaneous coding for both quantification with either amplification or direct probes, is not warranted.

In the evaluation of Group B streptococcus, the primary advantage of a DNA probe technique compared to traditional culture techniques is the rapidity of results. This advantage suggests that the most appropriate use of the DNA probe technique is in the setting of impending labor, for which prompt results could permit the initiation of intrapartum antibiotic therapy.

Many probes have been combined into panels of tests. For the purposes of this policy, other than the gastrointestinal pathogen panel and the respiratory virus panel, only individual probes are reviewed.

Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary.

The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.



10/26/2006: Policy added 

1/2/2007: Code reference section updated per the 2007 CPT/HCPCS revisions. Added CPT 87797 and 87798 to covered table. Added CPT 87799 to non-covered table with see policy note.

5/14/2007: Policy reviewed; updated to include enterovirus, staphylococcus aureus, and MRSA. CPT codes 87640-87641 added to covered table. CPT code 87948 added to non-covered table. Added ICD-9 codes 041.01, 041.02, 041.11, and V09.0 to covered table.

9/7/2007: Code reference section updated per annual ICD-9 code updates.

6/25/2008: Vancomycin resistance (eg., enterococcus vanA, vanB) amplified probe added as medically necessary. CPT 87500 added to covered

8/26/2008: Code reference section reviewed. CPT codes 87797, 87798, and 87799 removed

9/10/2008: Annual ICD-9 updates applied

03/11/2010: Code reference section updated. New CPT code 87493 added to non-covered table.

12/13/2011:  Policy description updated.  Medically necessary indications added for clostridium difficile, influenza virus, and trichomoniasis vaginalis.  Moved 87493 from the Non-Covered Codes table to the Covered Codes table. Added CPT codes 87501, 87502,  87503, and 87660 and ICD-9 codes 008.45, 131.00 - 131.09, and 487.0 - 488.19 to the Covered Codes table.

01/09/2013:  Added coverage guidelines for respiratory syncytial virus (RSV). Added ICD-9 code 079.6 and CPT codes 87631 , 87632 , and 87632 to the Code Reference section.

01/21/2014: Policy statement revised to change Candida species amplified probe from investigational to medically necessary. Added medically necessary indication for Trichomonas vaginalis amplified probe. Moved CPT code 87481 from non-covered to covered. Added the following new 2014 CPT code(s) to the Code Reference section: 87761.

12/31/2014: Policy description updated to add information regarding amplification techniques, Enterovirus, and Mycoplasma pneumoniae. Policy statement updated to add investigational indications for Gastrointestinal Pathogen Panel amplified probe, Mycobacterium tuberculosis quantification, and Mycoplasma pneumoniae direct probe, amplified probe, and quantification. Added medically necessary indications for Mycobacterium tuberculosis direct probe and amplified probe. Policy guidelines updated regarding quantification and probe techniques. Made the following correction in the Code Reference section: changed "87761" to "87661." Code Reference section updated to revise the description of the following CPT codes: 87504, 87502, 87503, 87631, 87632, and 87633. Added the following new 2015 CPT codes: 87623, 87624, 87625, 87806, 87505, 87506, and 87507.



Blue Cross Blue Shield Association Policy # 2.04.10 



This may not be a comprehensive list of procedure codes applicable to this policy.

The code(s) listed below are ONLY medically necessary if the procedure is performed according to the "Policy" section of this document.

Covered Codes 

Code Number




Candida species, direct probe technique 


Candida species, amplified probe technique


Chlamydia trachomatis, direct probe technique 


Chlamydia trachomatis,  amplified probe technique 


Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique


Cytomegalovirus, direct probe technique 


Cytomegalovirus,  amplified probe technique 


Cytomegalovirus,  quantification 


Infectious agent detection by nucleic acid (DNA or RNA); vancomycin resistance (eg, enterococcus species van A, van B), amplified probe technique


Infectious agent detection by nucleic acid (DNA or RNA); influenza virus; includes reverse transcription, when performed, and amplified probe technique, each type or subtype (Revised 01-01-2015) 


Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription and multiplex amplified probe technique, first 2 types or sub-types (Revised 01-01-2015)


Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription and multiplex amplified probe technique, each additional influenza virus type or sub-type beyond 2 (List separately in addition to code for primary procedure) (Revised 01-01-2015)


Gardnerella vaginalis, direct probe technique 


Hepatitis B virus, direct probe technique 


Hepatitis B virus, amplified probe technique 


Hepatitis B virus, quantification 


Hepatitis C virus, direct probe technique 


Hepatitis C virus, amplified probe technique 


Hepatitis C virus, quantification 


Herpes simplex virus, direct probe technique 


Herpes simplex virus,  amplified probe technique 


HIV-1, direct probe technique 


HIV-1, amplified probe technique 


HIV-1, quantification 


HIV-2, direct probe technique 


HIV-2, amplified probe technique 


HIV-2, quantification 


Mycobacterium species, direct probe technique 


Mycobacterium tuberculosis, direct probe technique 


Mycobacterium tuberculosis, amplified probe technique 


Mycobacterium avium intracellulare, direct probe technique 


Neisseria gonorrhoeae, direct probe technique 


Neisseria gonorrhoeae, amplified probe technique 


Papillomavirus, direct probe technique (Deleted 12-31-2014)


Papillomavirus, amplified probe technique (Deleted 12-31-2014)

87623Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44) (New 01-01-2015)
87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) (New 01-01-2015)
87625Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed (New 01-01-2015)


Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets (Revised 01-01-2015)


Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets (Revised 01-01-2015) 


Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets (Revised 01-01-2015) 


Staphylococcus aureus, amplified probe technique


Staphylococcus aureus, methicillin resistant, amplified probe technique


Streptococcus group A, direct probe technique 


Streptococcus, group B, amplified probe technique


Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique


Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique  

87806Infectious agent antigen detection by immunoassay with direct optical observation; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies (New 01-01-2015)

ICD-9 Procedure



ICD-9 Diagnosis


Clostridium difficile

010.0, 010.1, 010.8, 010.9, 011.0, 011.1, 011.2, 011.3, 011.4, 011.5, 011.6, 011.7, 011.8, 011.9, 012.0, 012.1, 012.2, 012.3, 012.8, 013.0, 013.1, 013.2, 013.3, 013.4, 013.5, 013.6, 013.8, 013.9, 014.0, 014.8, 015.0, 015.1, 015.2, 015.5, 015.7, 015.8, 015.9, 016.0, 016.1, 016.2, 016.3, 016.4, 016.5, 016.6, 016.7, 016.9, 017.0, 017.1, 017.2, 017.3, 017.4, 017.5, 017.6, 017.7, 017.8, 017.9, 018.0, 018.8, 018.9 

Tuberculosis , code range 

030.0, 030.1, 030.2, 030.3, 030.8, 030.9 

Diseases due to infection by Mycobacterium leprae 

031.0, 031.1, 031.2, 031.8, 031.9

Diseases due to other mycobacteria (includes mycobacterium avium-intracellualare) 


Streptococcus Group A


Streptococcus Group B


Methicillin susceptible Staphylococcus aureus in conditions classified elsewhere and of unspecfied site 


Methicillin resistant Staphyloccus aureus in conditions classified elsewhere and of unspecified site


Human immunodeficiency virus (HIV) disease 

054.0, 054.1, 054.4, 054.3, 054.4, 054.5, 054.6, 054.8, 054.9 

Herpes simplex, code range 


Human herpes virus 6 encephalitis


Other human herpes virus encephalitis


Human herpes virus 6 infection


Human herpes virus 7 infection


Other human herpes virus infection

070.20,070.21, 070.22, 070.23, 070.30, 070.31, 070.32, 070.33

Viral Hepatits B, code range


Acute or unspecified hepatitis C with hepatic coma


Chronic hepatitis C with hepatic coma


Acute or unspecified hepatitis C without mention of hepatic coma


Chronic hepatitic C without mention of hepatic coma


Cytomegaloviral disease


Respiratory syncytial virus (RSV) 


Parvovirus B19


Other specified chlamydial infection


Other specified viral infections ( includes papillomavirus)


Unspecified chlamydial infection

098.0, 098.10, 098.11, 098.12, 098.13, 098.14, 098.14, 098.15, 098.16, 098.17, 098.19, 098.2, 098.30, 098.31, 098.32, 098.33, 098.34, 098.35, 098.36, 098.37, 098.39, 098.4, 098.41, 098.43, 098.49, 098.50, 098.51, 098.52, 098.53, 098.59, 098.6, 098.7, 098.8, 098.81, 098.82, 098.83, 098.84, 098.85, 098.86, 098.89

Gonococcal infections, code range

131.00 - 131.09

Urogenital trichomoniasis code range


Legionnaires' disease

487.0 - 488.19

Influenza code range


Congenital cytomegalovirus infection


Other congenital infections ( includes herpes simplex, tuberculosis)


Human immodeficiency virus (HIV) asymptomatic


Infection with microorganisms resistant to penicillins 


Antenatal screening for Streptococcus B





Investigational Codes

Code Number




Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, direct probe technique


Bartonella henselae and Bartonella quintana, amplified probe technique


Bartonella henselae and Bartonella quintana, quantification


Borrelia burgdorferi, direct probe technique


Borrelia burgdorferi, amplified probe technique


Borrelia burgdorferi, quantification


Candida species, quantification


Chlamydia pneumoniae, direct probe technique


Chlamydia pneumoniae, amplified probe technique


Chlamydia pneumoniae, quantification


Chlamydia trachomatis, quantification


Enterovirus, amplified probe technique

87505Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets (New 01-01-2015)
87506Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets (New 01-01-2015)
87507Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets (New 01-01-2015)


Gardnerella vaginalis, amplified probe technique


Gardnerella vaginalis, quantification


Hepatitis G, direct probe technique


Hepatitis G,  amplified probe technique


Hepatitis G, quantification


Herpes Simplex virus, quantification


Herpes virus-6, direct probe technique


Herpes virus-6, amplified probe technique


Herpes virus-6, quantification


Legionella pneumophila, direct probe technique


Legionella pneumophila, amplified probe technique


Legionella pneumophila, quantification


Mycobacterium species, amplified probe technique


Mycobacterium species, quantification


Mycobacterium tuberculosis, quantification


Mycobacterium avium intracellulare, amplified probe technique


Mycobacterium avium intracellulare, quantification


Neisseria gonorrhoeae, quantification


Papillomavirus, quantification (Deleted 12-31-2014)


Streptococcus group A, amplified probe technique


Streptococcus group A, quantification

ICD-9 Procedure



ICD-9 Diagnosis